FSCN2

FSCN2 (fascin actin-bundling protein 2, retinal) makes a protein found specifically in the retina. Fascins crosslink actin into filament bundles that support dynamic parts of cells, and retinal fascin is thought to help build and maintain the disk structures inside photoreceptor (definition: A light-sensing cell in the retina. Rods (used for night and peripheral vision) and cones (used for color and detail) are the two types.) outer segments. Because of this proposed role, FSCN2 was investigated as a candidate gene for inherited retinal degeneration. An early study in Japanese families reported that a specific change (208delG) in FSCN2 caused autosomal dominant (definition: An inheritance pattern where a single altered copy of a gene, from just one parent, is enough to cause the condition.) retinitis pigmentosa, and a related report linked the same change to autosomal dominant macular degeneration. However, this reported association has since been challenged by studies in other populations, and the strength of the FSCN2–retinal disease link remains disputed. RP Hope's reviewed records classify FSCN2 as a disputed cause of retinitis pigmentosa rather than an established one.

In the original reports, people carrying the 208delG change were described with either typical retinitis pigmentosa or with a macular (central) form of degeneration, suggesting a range of possible appearances. Later case reports have instead described people with rare FSCN2 variants who had a cone or cone-rod dystrophy pattern, in which central and color/detail vision is affected relatively early. In one such case, a man in his sixties had roughly 20 years of blurred vision, reduced central acuity, and a distinctive pattern of pigment changes and photoreceptor (definition: A light-sensing cell in the retina. Rods (used for night and peripheral vision) and cones (used for color and detail) are the two types.) loss centered near the fovea. These descriptions come from single patients or very small numbers of people, so they cannot reliably predict how vision would change for any individual with an FSCN2 variant. Importantly, several studies found the reported FSCN2 change in people with normal vision and found that it did not track with disease within families, which is a key reason the association is disputed.

Researchers agree that FSCN2 is normally active in photoreceptors and that its protein helps organize actin, supporting photoreceptor (definition: A light-sensing cell in the retina. Rods (used for night and peripheral vision) and cones (used for color and detail) are the two types.) disk structure. In laboratory mice, deleting or disrupting the Fscn2 gene led to progressive photoreceptor degeneration and reduced retinal electrical responses, and in some models also to hearing loss. This animal evidence shows the gene is biologically important for the retina, but findings in mice do not establish that FSCN2 variants cause disease in humans and are not a treatment. It is well documented that the originally reported 208delG change also appears in people without retinal disease and in control populations, and that it did not consistently cosegregate with disease in tested families. Two large screens of families with autosomal dominant (definition: An inheritance pattern where a single altered copy of a gene, from just one parent, is enough to cause the condition.) retinitis pigmentosa did not identify disease-causing mutations in FSCN2.

The central uncertainty is whether variants in FSCN2 actually cause inherited retinal disease at all, or whether they are usually incidental findings. Some newer single-patient reports argue that certain rare FSCN2 missense variants might contribute to a cone or cone-rod dystrophy with a central pattern, but this is based on very limited evidence. Laboratory work suggests FSCN2 activity can be influenced by other retinal disease genes, such as the splicing factor PRPF31, but how this relates to human FSCN2 disease is not established. Because the evidence is conflicting and often limited to case reports or population screens, the clinical significance of an individual FSCN2 variant frequently remains uncertain and may be reported as a variant of uncertain significance.

RP Hope's reviewed records do not currently identify a gene-specific approved treatment for FSCN2-related retinal disease. Most FSCN2 research to date has focused on understanding the gene's function and on testing whether reported variants are truly disease-causing, rather than on therapies. Laboratory studies in cells and mice have explored how loss of FSCN2 affects photoreceptors and how other genes such as PRPF31 may regulate it, and one such study describes FSCN2 as a potential therapeutic target. These are early laboratory findings, not treatments available to patients, and they do not establish that FSCN2 causes human disease.

• Mouse studies of Fscn2 loss and photoreceptor structure

  Animal (laboratory) research.

  What was found:

  These mice showed progressive photoreceptor degeneration, abnormal outer segment disks, and reduced retinal electrical responses, and in some models hearing loss.

  Why it matters:

  This shows the gene is biologically important for the retina and supports its proposed role in photoreceptor disk structure.

  Limitation: Findings in mice do not confirm that human FSCN2 variants cause disease and are not a treatment.

• Original report linking FSCN2 to dominant retinitis pigmentosa

  Observational human study (case series with family screening).

  What was found:

  A specific change (208delG) was found in 14 patients from four families and reported in about 3.3% of the studied dominant RP patients, with typical RP findings.

  Why it matters:

  This is the study that first proposed FSCN2 as a retinal disease gene and is the basis for its historical listing.

  Limitation: Limited to one population, and later studies did not confirm the association, so this report alone does not establish causation.

• Reported FSCN2 change not associated with disease in Chinese individuals

  Observational human study (population and family screening).

  What was found:

  The change did not cosegregate with disease in several families, was present in normal family members, and was also found in 13 control subjects.

  Why it matters:

  This directly contradicted the original claim and is a main reason the FSCN2–RP link is considered disputed.

  Limitation: Focused on one specific change rather than every possible FSCN2 variant.

• No FSCN2 mutations found in a large dominant RP screen

  Observational human study (mutation prevalence screen).

  What was found:

  Disease-causing mutations were identified in about half of families, but none were found in FSCN2.

  Why it matters:

  A large systematic screen finding no FSCN2 mutations argues against it being a common cause of dominant RP.

  Limitation: Some regions of genes or certain mutation types may not be detected by the methods used.

• Recent case report of an FSCN2 variant with a cone-rod pattern

  Single-patient case report.

  What was found:

  He had a cone-rod dystrophy pattern with distinctive central pigment changes and photoreceptor loss, which the authors felt resembled earlier FSCN2 reports.

  Why it matters:

  It illustrates the ongoing debate, offering a possible argument for pathogenicity of certain rare FSCN2 variants.

  Limitation: One patient only; a single case cannot prove that the variant causes disease.

Because an FSCN2 result is often uncertain, families may find it helpful to focus on practical support and clear information rather than assumptions about the future. A good starting point is simply asking the person what kind of assistance, if any, they prefer, and respecting their independence. Low-vision rehabilitation, accessible technology, and support with transportation or school and workplace accommodations can help maintain daily activities when vision is affected. Emotional and community support can matter as much as medical care, and reading how others have navigated a diagnosis may help. For questions about inheritance and whether relatives might be affected, a genetic counselor is the appropriate person to interpret a disputed result.

• Given that the FSCN2–retinal disease association is disputed, does my clinical picture actually fit an FSCN2-related condition, or should another gene be considered?
• Was my FSCN2 variant classified as pathogenic, likely pathogenic, or a variant of uncertain significance, and what does that mean for me?
• Would testing other family members help clarify whether this variant tracks with vision problems in our family?
• Do my exam and imaging findings look more like retinitis pigmentosa, macular degeneration, or a cone/cone-rod dystrophy?
• Should I have additional or updated genetic testing to look for a more definitive cause?
• What kind of monitoring or low-vision support would you recommend based on my current vision, regardless of the genetic uncertainty?

If an FSCN2 variant appears on a genetic test report, it may be helpful to review the full result with a retinal specialist and a genetic counselor who can weigh it against your clinical findings and family history. Because the FSCN2–retinal disease link is disputed, it is especially reasonable to ask whether another gene might better explain the diagnosis and whether additional testing of family members would clarify the result. RP Hope's genetic testing resource explains what genetic testing involves and offers questions to bring to a genetic counselor. RP Hope's My RP Pathway can help you find resources appropriate to your stage, whether newly diagnosed or navigating an uncertain result.